Novel therapy for pediatric and adolescent kidney cancer

Amy L. Walz*, Conrad V. Fernandez, James I. Geller

*Corresponding author for this work

Research output: Contribution to journalReview article

Abstract

Pediatric and adolescent renal tumors account for approximately 7% of all new cancer diagnoses in the USA each year. The prognosis and treatment are varied based on factors including the underlying histology and tumor stage, with survival rates ranging from greater than 90% in favorable histology Wilms tumor to almost universally fatal in other disease types, including those patients with advanced stage malignant rhabdoid tumor and renal medullary carcinoma. In recent years, our understanding of the underlying genetic drivers of the different types of pediatric kidney cancer has dramatically increased, opening the door to utilization of new targeted biologic agents alone or in combination with conventional chemotherapy to improve outcomes. Several ongoing clinical trials are investigating the use of a variety of targeted agents in pediatric patients with underlying genetic aberrations. In this manuscript, the underlying biology and early phase clinical trials relevant to pediatric renal cancers are reviewed.

Original languageEnglish (US)
Pages (from-to)643-655
Number of pages13
JournalCancer and Metastasis Reviews
Volume38
Issue number4
DOIs
StatePublished - Dec 1 2019

Fingerprint

Kidney Neoplasms
Pediatrics
Histology
Clinical Trials
Rhabdoid Tumor
Kidney
Neoplasms
Medullary Carcinoma
Wilms Tumor
Biological Factors
Therapeutics
Survival Rate
Drug Therapy

Keywords

  • Kidney cancer
  • Novel therapy
  • Pediatric
  • Rhabdoid tumor
  • Wilms tumor

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Walz, Amy L. ; Fernandez, Conrad V. ; Geller, James I. / Novel therapy for pediatric and adolescent kidney cancer. In: Cancer and Metastasis Reviews. 2019 ; Vol. 38, No. 4. pp. 643-655.
@article{65049b5dff6341a793a570f92318480b,
title = "Novel therapy for pediatric and adolescent kidney cancer",
abstract = "Pediatric and adolescent renal tumors account for approximately 7{\%} of all new cancer diagnoses in the USA each year. The prognosis and treatment are varied based on factors including the underlying histology and tumor stage, with survival rates ranging from greater than 90{\%} in favorable histology Wilms tumor to almost universally fatal in other disease types, including those patients with advanced stage malignant rhabdoid tumor and renal medullary carcinoma. In recent years, our understanding of the underlying genetic drivers of the different types of pediatric kidney cancer has dramatically increased, opening the door to utilization of new targeted biologic agents alone or in combination with conventional chemotherapy to improve outcomes. Several ongoing clinical trials are investigating the use of a variety of targeted agents in pediatric patients with underlying genetic aberrations. In this manuscript, the underlying biology and early phase clinical trials relevant to pediatric renal cancers are reviewed.",
keywords = "Kidney cancer, Novel therapy, Pediatric, Rhabdoid tumor, Wilms tumor",
author = "Walz, {Amy L.} and Fernandez, {Conrad V.} and Geller, {James I.}",
year = "2019",
month = "12",
day = "1",
doi = "10.1007/s10555-019-09822-4",
language = "English (US)",
volume = "38",
pages = "643--655",
journal = "Cancer and Metastasis Reviews",
issn = "0167-7659",
publisher = "Springer Netherlands",
number = "4",

}

Novel therapy for pediatric and adolescent kidney cancer. / Walz, Amy L.; Fernandez, Conrad V.; Geller, James I.

In: Cancer and Metastasis Reviews, Vol. 38, No. 4, 01.12.2019, p. 643-655.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Novel therapy for pediatric and adolescent kidney cancer

AU - Walz, Amy L.

AU - Fernandez, Conrad V.

AU - Geller, James I.

PY - 2019/12/1

Y1 - 2019/12/1

N2 - Pediatric and adolescent renal tumors account for approximately 7% of all new cancer diagnoses in the USA each year. The prognosis and treatment are varied based on factors including the underlying histology and tumor stage, with survival rates ranging from greater than 90% in favorable histology Wilms tumor to almost universally fatal in other disease types, including those patients with advanced stage malignant rhabdoid tumor and renal medullary carcinoma. In recent years, our understanding of the underlying genetic drivers of the different types of pediatric kidney cancer has dramatically increased, opening the door to utilization of new targeted biologic agents alone or in combination with conventional chemotherapy to improve outcomes. Several ongoing clinical trials are investigating the use of a variety of targeted agents in pediatric patients with underlying genetic aberrations. In this manuscript, the underlying biology and early phase clinical trials relevant to pediatric renal cancers are reviewed.

AB - Pediatric and adolescent renal tumors account for approximately 7% of all new cancer diagnoses in the USA each year. The prognosis and treatment are varied based on factors including the underlying histology and tumor stage, with survival rates ranging from greater than 90% in favorable histology Wilms tumor to almost universally fatal in other disease types, including those patients with advanced stage malignant rhabdoid tumor and renal medullary carcinoma. In recent years, our understanding of the underlying genetic drivers of the different types of pediatric kidney cancer has dramatically increased, opening the door to utilization of new targeted biologic agents alone or in combination with conventional chemotherapy to improve outcomes. Several ongoing clinical trials are investigating the use of a variety of targeted agents in pediatric patients with underlying genetic aberrations. In this manuscript, the underlying biology and early phase clinical trials relevant to pediatric renal cancers are reviewed.

KW - Kidney cancer

KW - Novel therapy

KW - Pediatric

KW - Rhabdoid tumor

KW - Wilms tumor

UR - http://www.scopus.com/inward/record.url?scp=85076276191&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85076276191&partnerID=8YFLogxK

U2 - 10.1007/s10555-019-09822-4

DO - 10.1007/s10555-019-09822-4

M3 - Review article

C2 - 31811552

AN - SCOPUS:85076276191

VL - 38

SP - 643

EP - 655

JO - Cancer and Metastasis Reviews

JF - Cancer and Metastasis Reviews

SN - 0167-7659

IS - 4

ER -